17,17-ethylenedioxy-2-methoxyestra-1,3,5(10)-trien-3-ol 3-benzyl ether | 477951-70-5

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 类固醇和类固醇衍生物
• 英文名称: 17,17-ethylenedioxy-2-methoxyestra-1,3,5(10)-trien-3-ol 3-benzyl ether
• 英文别名: (8'R,9'S,13'S,14'S)-2'-methoxy-13'-methyl-3'-phenylmethoxyspiro[1,3-dioxolane-2,17'-7,8,9,11,12,14,15,16-octahydro-6H-cyclopenta[a]phenanthrene]
• CAS: 477951-70-5
• 化学式: C₂₈H₃₄O₄
• 分子量: 434.576
• InChiKey: YWXOWIONVOHQNT-FVJFVQOASA-N

计算性质

• 辛醇/水分配系数(LogP)：
  5.8
• 重原子数：
  32
• 可旋转键数：
  4
• 环数：
  6.0
• sp3杂化的碳原子比例：
  0.57
• 拓扑面积：
  36.9
• 氢给体数：
  0
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  17,17-ethylenedioxy-2-methoxyestra-1,3,5(10)-trien-3-ol 3-benzyl ether 在 pyridinium perbromate 、 乙二醇 作用下， 以 乙二醇二甲醚 为溶剂， 生成
  参考文献：
  名称：

  17SS-HSD1 and STS inhibitors

  摘要：

  本发明涉及新型取代类固醇衍生物，这些衍生物代表17β-羟基类固醇脱氢酶I（17β-HSD1）的选择性抑制剂，此外，它们可能代表类固醇硫酸酶的抑制剂，以及它们的盐，含有这些化合物的药物制剂以及这些化合物的制备方法。此外，本发明涉及所述新型取代类固醇衍生物的治疗用途，特别是它们在治疗、抑制、预防或预防类固醇激素依赖性疾病或紊乱中的使用，例如需要抑制17β-羟基类固醇脱氢酶I和/或类固醇硫酸酶酶的依赖性疾病或紊乱，以及需要降低内源性17β-雌二醇浓度的疾病或紊乱。

  公开号：

  US20060281710A1
• 作为产物：
  描述：

  2-methoxy-3-benzyloxyestra-1,3,5 (10)-triene-17β-ol 在 jones reagent 、 对甲苯磺酸 、 原甲酸三乙酯 作用下， 以 二氯甲烷 、 丙酮 为溶剂， 反应 16.0h， 生成 17,17-ethylenedioxy-2-methoxyestra-1,3,5(10)-trien-3-ol 3-benzyl ether
  参考文献：
  名称：

  Synthesis and antimitotic activity of novel 2-methoxyestradiol analogs

  摘要：

  The syntheses and antimitotic activity of several novel 2-methoxyestradiol analogs are described. Structural modifications investigated include introduction of additional unsaturation in rings B and D; inversion at C-13; and substitution at the C-2, C-15, C-16, and C-7alpha positions. Of 15 analogs synthesized, 2 have demonstrated superior biological activities compared to 2-methoxyestradiol. (C) 2002 Elsevier Science Inc. All rights reserved.

  DOI：

  10.1016/s0039-128x(02)00066-1

文献信息

• Novel 2-alkoxyestradiol analogs with antiproliferative and antimitotic activity
  申请人：SOUTHWEST FOUNDATION FOR BIOMEDICAL RESEARCH

  公开号：US20030229061A1

  公开（公告）日：2003-12-11

  The application discloses novel 2-alkoxyestradiol analogs which exhibit anti-proliferative properties, and methods of making and using such compounds to inhibit undesired cell proliferation and tumor growth. Additionally, methods are disclosed of treating diseases associated with undesired angiogenesis and undesired proliferation, and methods of treating infectious disease wherein the infectious agent is particularly susceptible to inhibition by agents that disrupt microtubule organization and function.

  本发明披露了新型2-烷氧基雌二醇类似物，该类似物具有抗增殖特性，并公开了制备和使用这些化合物以抑制不良细胞增殖和肿瘤生长的方法。此外，还披露了治疗与不良血管生成和不良增殖有关的疾病的方法，以及治疗感染疾病的方法，其中感染剂特别易受到破坏微管组织和功能的药物抑制。
• US6593321B2
  申请人：——

  公开号：US6593321B2

  公开（公告）日：2003-07-15
• US6852710B2
  申请人：——

  公开号：US6852710B2

  公开（公告）日：2005-02-08
• [EN] NOVEL 2-ALKOXYESTRADIOL ANALOGS WITH ANTIPROLIFERATIVE AND ANTIMITOTIC ACTIVITY<br/>[FR] NOUVEAUX ANALOGUES 2-ALCOXYESTRADIOL A ACTIVITE ANTIPROLIFERATIVE ET ANTIMITOTIQUE
  申请人：SOUTHWEST FOUND BIOMED RES

  公开号：WO2002100877A1

  公开（公告）日：2002-12-19

  The application discloses novel 2-alkoxyestradiol analogs which exhibit antiproliferative properties, and methods of making and using such compounds to inhibit undesired cell proliferation and tumor growth. Additionally, methods are disclosed of treating diseases associated with undesired angiogenesis and undesired proliferation, and methods of treating infectious disease wherein the infectious agent is particularly susceptible to inhibition by agents that disrupt microtubule organization and function.
• 17SS-HSD1 and STS inhibitors
  申请人：Messinger Josef

  公开号：US20060281710A1

  公开（公告）日：2006-12-14

  The present invention relates to novel substituted steroid derivatives which represent selectiv inhibitors of the 17β-hydroxysteroid dehydrogenase type I (17β-HSD1) and, in addition, which may represent inhibitors of the steroid sulphatase, as well as to their salts, to pharmaceutical preparations containing these compounds and to processes for the preparation of these compounds. Furthermore, the invention concerns the therapeutic use of said novel substituted steroid derivatives, particularly their use in the treatment, inhibition, prophylaxis or prevention of steroid hormone dependent diseases or disorders, such as steroid hormone dependent diseases or disorders requiring the inhibition of 17β-hydroxysteroid dehydrogenase type I and/or steroid sulphatase enzymes and/or requiring the lowering of the endogenous 17β-estradiol concentration.

  本发明涉及新型取代类固醇衍生物，这些衍生物代表17β-羟基类固醇脱氢酶I（17β-HSD1）的选择性抑制剂，此外，它们可能代表类固醇硫酸酶的抑制剂，以及它们的盐，含有这些化合物的药物制剂以及这些化合物的制备方法。此外，本发明涉及所述新型取代类固醇衍生物的治疗用途，特别是它们在治疗、抑制、预防或预防类固醇激素依赖性疾病或紊乱中的使用，例如需要抑制17β-羟基类固醇脱氢酶I和/或类固醇硫酸酶酶的依赖性疾病或紊乱，以及需要降低内源性17β-雌二醇浓度的疾病或紊乱。